Cha Cha Yang's questions to TG Therapeutics Inc (TGTX) leadership • Q2 2025
Question
Cha Cha Yang, on behalf of Roger Sange, asked about patient adherence and persistence with BRIUMVI's biannual infusion schedule and also requested specific financial guidance for the third quarter.
Answer
Chief Commercial Officer Adam Waldman clarified that the company does not provide specific quarterly guidance, but reiterated the full-year guidance and the expected growth trend from Q3 to Q4. Regarding adherence, he stated that patient persistence at week 24 and preliminary data at week 48 remain strong and are tracking above internal expectations and published data for other CD20 therapies.